Skye Bioscience, Inc. (SKYE)

Over the past six months, Skye Bioscience's stock has declined by 43.61%, with the share price at $0.90 as of May 7, 2026. Key events include the failure of the CBeyond Phase 2a study of nimacimab monotherapy to meet its primary endpoint, leading to a significant stock drop. Positive data from the extension phase of the Phase 2a trial and interim 52-week results for nimacimab combined with semaglutide showed promising weight loss. Skye reported Q4 and full-year 2025 financial results and received a Nasdaq deficiency letter due to its stock price being below $1.00. The company treated the first patient in its nimacimab higher-dose expansion study, with topline data expected in Q4 2026, and had an earnings report for Q1 2026.

Information regarding specific demand seasonality for Skye Bioscience, Inc.'s products and services is not readily available. As a clinical-stage biotechnology company, its revenue generation is primarily tied to research and development milestones, clinical trial progress, and potential future commercialization, rather than seasonal consumer demand for established products. The demand for its product candidates, such as nimacimab, would be driven by the prevalence of the diseases they aim to treat and the efficacy and safety profiles demonstrated in clinical trials, rather than seasonal fluctuations.

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for metabolic health by modulating G-protein-coupled receptors (GPCRs), primarily addressing obesity and related diseases. Their lead product candidate is nimacimab, a CB1 targeting antibody, being developed as a standalone anti-obesity therapy or in combination with GLP-1 receptor agonists. The company is also working on SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension, and SBI-200 for various eye diseases.

Skye Bioscience, Inc. is headquartered in San Diego, California, United States. They also have a research facility in Langley, British Columbia, Canada, acquired from Emerald Health Therapeutics, Inc., which is currently not operational but holds a dealer's license for research on certain controlled substances.

Skye Bioscience's reputation has been affected by mixed clinical trial results. The failure of nimacimab monotherapy in the Phase 2a CBeyond trial negatively impacted its standing. However, positive results for nimacimab in combination with semaglutide have helped mitigate some damage and reinforced the company's strategy for combination therapies. The ongoing higher-dose expansion study indicates a continued commitment to advancing its lead candidate.

Skye Bioscience's ownership is distributed among institutional investors (8.45% to 74.46%), insiders (57.54%), the general public (14% to 31.75%), and private equity firms (38%). Major institutional owners include 5AM Venture Management, LLC, Versant Venture Management, LLC, and Baker Bros. Advisors Lp. Andrew Schwab owns the most shares among insiders.